CAMBRIDGE, Mass., April 4 /PRNewswire/ -- TolerRx today announces the acquisition of certain intellectual property and material assets from Diabetogen Biosciences. TolerRx has acquired access to technology under a patent application and a licensing agreement between Diabetogen and The L'Institut National de La Sante et de La Recherche Medicale (INSERM) relating to the therapeutic use of anti-CD3 antibodies in autoimmune diseases. In addition, TolerRx has acquired rights to technology and material relating to a panel of fully human anti-CD3 antibodies under a licensing agreement between Diabetogen and Abgenix, Inc. Financial terms of the agreement were not disclosed.
"The acquisition of these assets facilitates our objective to position TolerRx as the market leader with anti-CD3 products," stated Dr. Douglas J. Ringler, President and Chief Executive Officer of TolerRx. "In particular, we are dedicated to commercializing our lead product targeting CD3, TRX4, in multiple autoimmune disease indications, and this acquisition provides us with additional resources necessary to protect those markets."
TolerRx is a biopharmaceutical company specializing in the discovery, development, and commercialization of novel therapies to treat patients with immune-mediated diseases. TRX4 is a humanized anti-CD3 monoclonal antibody that has completed an investigator-sponsored Phase II clinical trial in patients with new onset Type 1 diabetes. TolerRx's TRX1 is a humanized anti- CD4 monoclonal antibody that has been partnered with Genentech, Inc. and is in Phase Ib clinical development. TolerRx is also developing new products to induce immunological tolerance for the treatment of autoimmune diseases and to remove tolerance for the treatment of cancer or chronic viral diseases. For more information, please visit http://www.tolerrx.com/.
INSERM is the pre-eminent French biomedical research organization. INSERM's mission is to conduct research and support research enterprise in biology, medicine, and health. INSERM consists of 360 laboratories, 24 clinical centers, and 7 joint laboratories with EU and US universities. INSERM has a long tradition of working with the biomedical industry worldwide. INSERM actively seeks patent protection and grants access to its technology portfolio through licensing and ensures the availability and dissemination of its biomedical resources. INSERM's active portfolio consists of 587 patent families in biotechnology/biopharma, 508 research and development contracts, and 490 licenses. Marketed products include two HBV vaccines, pharmaceuticals, medical devices, diagnostic kits, and research tools. INSERM has been instrumental in the creation of 60 spin-off companies since 1998.
Thomas A. Shea
Contact: Thomas A. Shea of TolerRx, Inc., +1-617-452-1300,email@example.com